Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2026-06-08
Target enrollment:
Participant gender:
Summary
This study is designed to assess the antitumor activity of combination therapy of SMT-NK
(allogeneic natural killer cells) and pembrolizumab versus pembrolizumab monotherapy in
patients with advanced biliary tract cancer